H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

11/22/23 7:15:52 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLDI

Date	Price Target	Rating	Analyst
11/22/2023	$11.00	Buy	H.C. Wainwright
10/9/2023	$9.00	Outperform	Robert W. Baird